Combination therapy with pioglitazone/exenatide improves beta‐cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3‐ year follow‐up of the Qatar study-Reference-Cited by-同舟云学术

Combination therapy with pioglitazone/exenatide improves beta‐cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3‐ year follow‐up of the Qatar study

Published:2020-09-03 Issue:12 Volume:22 Page:2287-2294
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Abdul‐Ghani Muhammad¹²^ORCID,Migahid Osama³,Megahed Ayman³,DeFronzo Ralph A.¹^ORCID,Al‐Ozairi Ebaa²,Jayyousi Amin³

Affiliation:

1. Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio Texas USA

2. Dasman Diabetes Institute Kuwait City Kuwait

3. Academic Health System, Hamad General Hospital Doha Qatar

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14153

Reference21 articles.

1. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

2. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

3. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

4. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial;Abdul‐Ghani MA;Diabetes Obes Metab.,2017

5. Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines;BMC Medicine;2024-09-04

2. Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach;Human Cell;2023-12-01

3. Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study;Alimentary Pharmacology & Therapeutics;2023-02-23

4. Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies;Diabetes, Obesity and Metabolism;2022-06-29

5. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations;Journal of Diabetes;2022-04-17